Psychosis are a group of disorders with serious distortion of thought, behavior, recognition
of reality and perception. The patient may have delusions and hallucinations and may have
misperception and wrong evaluation of situation, facts or other people.
The Global Antipsychotic Drugs Market is expected to reach around USD 18.5 billion by
the end of the forecast period and is expected to grow at a CAGR of ~4.3%.
The most critical market driving factor for anti-psychotic drugs is the rising cases of
psychosis and mental disorders. Following are some estimates about psychosis according to
the World Health Organization (WHO)
Depression affects an estimated 300 million people in the world.
Bipolar affective disorder takes a toll on about 60 million people worldwide.
Schizophrenia, a severe mental disorder, affects about 21 million people worldwide.
Dementia has a prevalence in about 47.5 million people worldwide
One fourth of people are affected by mental or neurological disorders at some point
in their lives.
The current number of untapped patients are of an order of around 450 million
currently suffering from such conditions.
The treatment scenario is no different and the least it is said the better. According to WHO,
the gap between the unmet needs in low- and middle-income countries is between 76% and
85% of people with mental disorders. Even in high-income countries the unmet medical
needs gap is of an order of 35% and 50% of people with mental disorders. Thus there exists
a huge market with unmet medical needs which needs to be tapped. Other very important
market driving factor is increasing focus of governments and health care organizations on
mental health. For example, WHO's initiated its Mental Health Gap Action Programme in
2008, to expand the coverage of mental health treatment and service across the world.
Some of the key players in this market are: Eli Lilly & Co., Bristol-Myers Squibb,
AstraZeneca, Pfizer inc., GlaxoSmithKline plc., Johnson & Johnson and others.
Get Sample Copy at http://bit.ly/2pPGoBP .
However there are huge formidable barriers which remain a challenge to expand the market
and the anti-psychotic drugs market has shown growth par below their potential market due
to a host of factors. The critical market restraint is the poor efficiency and efficacy of anti-
psychotic drugs. The side effects of these drugs is another depressing story to tell, which
ranges from insomnia, drowsiness, vomiting to the high addiction rate. Social stigma also
constraints the market with an estimated two-thirds of patients never seeking help. The
poor drug development pipeline is a future market threat. The drug pipeline for anti-
psychotics is devoid of any novel acting drug candidate. Strict regulatory framework is
another deterrent for companies developing anti-psychotics.
Intended Audience